Scopolamine impairs recall of one-trial stimulus-reward association in monkeys.
Performance of three rhesus monkeys on a test of one-trial stimulus-reward association, in which recall intervals ranged from 0.5 to 6.5 min, was evaluated during nondrug-control conditions and following administration of the muscarinic-receptor blocker scopolamine. During control sessions, performance averaged 78% correct responses. Following administration of 10.0 and 17.8 micrograms/kg of scopolamine, performance fell significantly, to 69% and 63% correct responses, respectively. This dose-dependent impairment in recall was similar to the impairment we reported previously in recognition. Although the results thus failed to support a suggestion derived from behavioral electrophysiological findings that stimulus-reward association might be more vulnerable to scopolamine than stimulus recognition, they provide additional evidence for a cholinergic contribution to cognitive memory.
Aigner
T G
TG
Laboratory of Neuropsychology, National Institute of Mental Health, Bethesda, MD 20892.
Mishkin
M
M
D000818:Animals; D001245:Association Learning / Q000187:drug effects*; D001288:Attention / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008032:Limbic System / Q000187:drug effects*; D008253:Macaca mulatta; D008297:Male; D011939:Mental Recall / Q000187:drug effects*; D009434:Neural Pathways / Q000187:drug effects; D010364:Pattern Recognition, Visual / Q000187:drug effects; D016548:Prosencephalon / Q000187:drug effects*; D011976:Receptors, Muscarinic / Q000187:drug effects*; D012601:Scopolamine / Q000494:pharmacology*; D014793:Visual Cortex / Q000187:drug effects*
D011976:Receptors, Muscarinic; D012601:Scopolamine